{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:33:44Z","timestamp":1787315624949,"version":"build-2736575974"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,7,24]],"date-time":"2017-07-24T00:00:00Z","timestamp":1500854400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,7,24]],"date-time":"2017-07-24T00:00:00Z","timestamp":1500854400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Peritonitis remains a major cause of morbidity and mortality during chronic peritoneal dialysis (PD). Glucose-based PD fluids reduce immunological defenses in the peritoneal cavity. Low concentrations of peritoneal extracellular glutamine during PD may contribute to this immune deficit. For these reasons we have developed a clinical assay to measure the function of the immune-competent cells in PD effluent from PD patients. We then applied this assay to test the impact on peritoneal immune-competence of PD fluid supplementation with alanyl-glutamine (AlaGln) in 6 patients in an open-label, randomized, crossover pilot trial (EudraCT 2012-004004-36), and related the functional results to transcriptome changes in PD effluent cells.\n                    <jats:italic>Ex-vivo<\/jats:italic>\n                    stimulation of PD effluent peritoneal cells increased release of interleukin (IL) 6 and tumor necrosis factor (TNF) \u03b1. Both IL-6 and TNF-\u03b1 were lower at 1\u2009h than at 4\u2009h of the peritoneal equilibration test but the reductions in cytokine release were attenuated in AlaGln-supplemented samples. AlaGln-supplemented samples exhibited priming of IL-6-related pathways and downregulation of TNF-\u03b1 upstream elements. Results from measurement of cytokine release and transcriptome analysis in this pilot clinical study support the conclusion that suppression of PD effluent cell immune function in human subjects by standard PD fluid is attenuated by AlaGln supplementation.\n                  <\/jats:p>","DOI":"10.1038\/s41598-017-05872-2","type":"journal-article","created":{"date-parts":[[2017,7,18]],"date-time":"2017-07-18T05:51:10Z","timestamp":1500357070000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Functional and Transcriptomic Characterization of Peritoneal Immune-Modulation by Addition of Alanyl-Glutamine to Dialysis Fluid"],"prefix":"10.1038","volume":"7","author":[{"given":"Rebecca","family":"Herzog","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilian","family":"Kuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias","family":"Gluexam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Pils","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Spittler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manoj K.","family":"Bhasin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth L.","family":"Alper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Vychytil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Aufricht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0803-614X","authenticated-orcid":false,"given":"Klaus","family":"Kratochwill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,7,24]]},"reference":[{"key":"5872_CR1","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1093\/ndt\/gfq003","volume":"25","author":"DW Evans","year":"2010","unstructured":"Evans, D. W., Ryckelynck, J. P., Fabre, E. & Verger, C. Peritonitis-free survival in peritoneal dialysis: an update taking competing risks into account. Nephrol Dial Transplant \n                           25, 2315\u20132322, doi:10.1093\/ndt\/gfq003 (2010).","journal-title":"Nephrol Dial Transplant"},{"key":"5872_CR2","doi-asserted-by":"publisher","unstructured":"Pajek, J. et al. Outcomes of Peritoneal Dialysis Patients and Switching to Hemodialysis: A Competing Risks Analysis. Peritoneal Dialysis International, doi:10.3747\/pdi.2012.00248 (2014).","DOI":"10.3747\/pdi.2012.00248"},{"key":"5872_CR3","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.2215\/CJN.01480212","volume":"7","author":"J Perl","year":"2012","unstructured":"Perl, J. et al. Changes in Patient and Technique Survival over Time among Incident Peritoneal Dialysis Patients in Canada. Clinical Journal of the American Society of Nephrology \n                           7, 1145\u20131154, doi:10.2215\/cjn.01480212 (2012).","journal-title":"Clinical Journal of the American Society of Nephrology"},{"key":"5872_CR4","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1038\/nrneph.2012.13","volume":"8","author":"E Garcia-Lopez","year":"2012","unstructured":"Garcia-Lopez, E., Lindholm, B. & Davies, S. An update on peritoneal dialysis solutions. Nat Rev Nephrol \n                           8, 224\u2013233, doi:10.1038\/nrneph.2012.13 (2012).","journal-title":"Nat Rev Nephrol"},{"key":"5872_CR5","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1111\/j.1525-1594.2009.00735.x","volume":"33","author":"S Koball","year":"2009","unstructured":"Koball, S., Korten, G., Stange, J., Schmidt, R. & Mitzner, S. Biocompatibility assessment of peritoneal dialysis solutions with a new in vitro model of preconditioned human HL60 cells. Artif Organs \n                           33, 544\u2013550, doi:10.1111\/j.1525-1594.2009.00735.x (2009).","journal-title":"Artif Organs"},{"issue":"Suppl 88","key":"5872_CR6","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1046\/j.1523-1755.2003.08809.x","volume":"64","author":"R Mackenzie","year":"2003","unstructured":"Mackenzie, R., Holmes, C. J., Jones, S., Williams, J. D. & Topley, N. Clinical indices of in vivo biocompatibility: the role of ex vivo cell function studies and effluent markers in peritoneal dialysis patients. Kidney Int Suppl \n                           64(Suppl 88), S84\u201393 (2003).","journal-title":"Kidney Int Suppl"},{"key":"5872_CR7","doi-asserted-by":"publisher","first-page":"1447","DOI":"10.1038\/ki.1996.204","volume":"49","author":"N Topley","year":"1996","unstructured":"Topley, N. et al. Biocompatibility of bicarbonate buffered peritoneal dialysis fluids: influence on mesothelial cell and neutrophil function. Kidney Int \n                           49, 1447\u20131456 (1996).","journal-title":"Kidney Int"},{"key":"5872_CR8","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1681\/ASN.V72218","volume":"7","author":"N Topley","year":"1996","unstructured":"Topley, N. et al. In vitro effects of bicarbonate and bicarbonate-lactate buffered peritoneal dialysis solutions on mesothelial and neutrophil function. Journal of the American Society of Nephrology: JASN \n                           7, 218\u2013224 (1996).","journal-title":"Journal of the American Society of Nephrology: JASN"},{"key":"5872_CR9","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1023\/A:1012806815330","volume":"25","author":"A Brauner","year":"2001","unstructured":"Brauner, A., Hylander, B., Jacobson, S. H., Moshfegh, A. & Lundahl, J. Increased expression of CD25 and HLA-DR on lymphocytes recruited into the peritoneal cavity in non-infected CAPD patients. Inflammation \n                           25, 399\u2013404 (2001).","journal-title":"Inflammation"},{"key":"5872_CR10","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.cca.2013.02.027","volume":"421","author":"SM de Lima","year":"2013","unstructured":"de Lima, S. M. et al. Inflammation, neoangiogenesis and fibrosis in peritoneal dialysis. Clin Chim Acta \n                           421, 46\u201350, doi:10.1016\/j.cca.2013.02.027 (2013).","journal-title":"Clin Chim Acta"},{"issue":"Suppl 1","key":"5872_CR11","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.1681\/ASN.V13suppl_1s97","volume":"13","author":"S Jones","year":"2002","unstructured":"Jones, S. et al. Continuous dialysis with bicarbonate\/lactate-buffered peritoneal dialysis fluids results in a long-term improvement in ex vivo peritoneal macrophage function. Journal of the American Society of Nephrology: JASN \n                           13(Suppl 1), S97\u2013103 (2002).","journal-title":"Journal of the American Society of Nephrology: JASN"},{"key":"5872_CR12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/089686089101100105","volume":"11","author":"S Lewis","year":"1991","unstructured":"Lewis, S. & Holmes, C. Host defense mechanisms in the peritoneal cavity of continuous ambulatory peritoneal dialysis patients. 1. Perit Dial Int \n                           11, 14\u201321 (1991).","journal-title":"Perit Dial Int"},{"key":"5872_CR13","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1177\/089686080602600414","volume":"26","author":"M Erixon","year":"2006","unstructured":"Erixon, M. et al. How to avoid glucose degradation products in peritoneal dialysis fluids. Perit Dial Int \n                           26, 490\u2013497 (2006).","journal-title":"Perit Dial Int"},{"key":"5872_CR14","doi-asserted-by":"publisher","unstructured":"Cho, Y. et al. Biocompatible dialysis fluids for peritoneal dialysis. Cochrane Database Syst Rev \n                           3, CD007554, doi:10.1002\/14651858.CD007554.pub2 (2014).","DOI":"10.1002\/14651858.CD007554.pub2"},{"key":"5872_CR15","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1128\/CDLI.5.4.556-560.1998","volume":"5","author":"RS Wallis","year":"1998","unstructured":"Wallis, R. S. et al. Measurement of induced cytokines in AIDS clinical trials using whole blood: A preliminary report. Clinical and Diagnostic Laboratory Immunology \n                           5, 556\u2013560 (1998).","journal-title":"Clinical and Diagnostic Laboratory Immunology"},{"key":"5872_CR16","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1097\/01.shk.0000191379.62897.1d","volume":"25","author":"M Ploder","year":"2006","unstructured":"Ploder, M. et al. Lipopolysaccharide-induced tumor necrosis factor alpha production and not monocyte human leukocyte antigen-DR expression is correlated with survival in septic trauma patients. Shock \n                           25, 129\u2013134, doi:10.1097\/01.shk.0000191379.62897.1d (2006).","journal-title":"Shock"},{"key":"5872_CR17","doi-asserted-by":"publisher","first-page":"697972","DOI":"10.1155\/2013\/697972","volume":"2013","author":"A Schildberger","year":"2013","unstructured":"Schildberger, A., Rossmanith, E., Eichhorn, T., Strassl, K. & Weber, V. Monocytes, peripheral blood mononuclear cells, and THP-1 cells exhibit different cytokine expression patterns following stimulation with lipopolysaccharide. Mediators Inflamm \n                           2013, 697972, doi:10.1155\/2013\/697972 (2013).","journal-title":"Mediators Inflamm"},{"key":"5872_CR18","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1096\/fasebj.13.3.563","volume":"13","author":"A Spittler","year":"1999","unstructured":"Spittler, A. et al. Immunomodulatory effects of glycine on LPS-treated monocytes: reduced TNF-alpha production and accelerated IL-10 expression. FASEB J \n                           13, 563\u2013571 (1999).","journal-title":"FASEB J"},{"key":"5872_CR19","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/00000658-200301000-00015","volume":"237","author":"R Exner","year":"2003","unstructured":"Exner, R. et al. Perioperative GLY-GLN infusion diminishes the surgery-induced period of immunosuppression: accelerated restoration of the lipopolysaccharide-stimulated tumor necrosis factor-alpha response. Ann Surg \n                           237, 110\u2013115, doi:10.1097\/01.SLA.0000041040.98684.CB (2003).","journal-title":"Ann Surg"},{"key":"5872_CR20","doi-asserted-by":"publisher","unstructured":"Tao, K. M. et al. Glutamine supplementation for critically ill adults. Cochrane Database Syst Rev \n                           9, CD010050, doi:10.1002\/14651858.CD010050.pub2 (2014).","DOI":"10.1002\/14651858.CD010050.pub2"},{"key":"5872_CR21","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nrg2484","volume":"10","author":"Z Wang","year":"2009","unstructured":"Wang, Z., Gerstein, M. & Snyder, M. RNA-Seq: a revolutionary tool for transcriptomics. Nat Rev Genet \n                           10, 57\u201363, doi:10.1038\/nrg2484 (2009).","journal-title":"Nat Rev Genet"},{"key":"5872_CR22","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1681\/ASN.V981499","volume":"9","author":"RK MacKenzie","year":"1998","unstructured":"MacKenzie, R. K. et al. Bicarbonate\/lactate- and bicarbonate-buffered peritoneal dialysis fluids improve ex vivo peritoneal macrophage TNFalpha secretion. Journal of the American Society of Nephrology: JASN \n                           9, 1499\u20131506 (1998).","journal-title":"Journal of the American Society of Nephrology: JASN"},{"key":"5872_CR23","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/S0272-6386(00)70309-X","volume":"35","author":"RK Mackenzie","year":"2000","unstructured":"Mackenzie, R. K. et al. In vivo exposure to bicarbonate\/lactate- and bicarbonate-buffered peritoneal dialysis fluids improves ex vivo peritoneal macrophage function. Am J Kidney Dis \n                           35, 112\u2013121 (2000).","journal-title":"Am J Kidney Dis"},{"key":"5872_CR24","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1089\/109629603766956960","volume":"4","author":"W Heagy","year":"2003","unstructured":"Heagy, W. et al. Lower levels of whole blood LPS-stimulated cytokine release are associated with poorer clinical outcomes in surgical ICU patients. Surg Infect (Larchmt) \n                           4, 171\u2013180, doi:10.1089\/109629603766956960 (2003).","journal-title":"Surg Infect (Larchmt)"},{"key":"5872_CR25","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1093\/bja\/aes248","volume":"109","author":"I Sulyok","year":"2012","unstructured":"Sulyok, I. et al. Effect of preoperative fever-range whole-body hyperthermia on immunological markers in patients undergoing colorectal cancer surgery. Br J Anaesth \n                           109, 754\u2013761, doi:10.1093\/bja\/aes248 (2012).","journal-title":"Br J Anaesth"},{"key":"5872_CR26","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1177\/089686080202200604","volume":"22","author":"T Liberek","year":"2002","unstructured":"Liberek, T. et al. Generation of TNFalpha and interleukin-6 by peritoneal macrophages after overnight dwells with bicarbonate- or lactate-buffered dialysis fluid. Perit Dial Int \n                           22, 663\u2013669 (2002).","journal-title":"Perit Dial Int"},{"key":"5872_CR27","doi-asserted-by":"publisher","unstructured":"Raby, A. C. et al. Toll-Like Receptors 2 and 4 Are Potential Therapeutic Targets in Peritoneal Dialysis-Associated Fibrosis. Journal of the American Society of Nephrology: JASN, doi:10.1681\/asn.2015080923 (2016).","DOI":"10.1681\/asn.2015080923"},{"key":"5872_CR28","doi-asserted-by":"crossref","unstructured":"Aufricht, C. et al. Biomarker research to improve clinical outcomes in peritoneal dialysis \u2013 consensus of the European Training and Research in Peritoneal Dialysis (EuTRiPD) network. in press (2017).","DOI":"10.1016\/j.kint.2017.02.037"},{"key":"5872_CR29","doi-asserted-by":"publisher","first-page":"545467","DOI":"10.1155\/2015\/545467","volume":"2015","author":"P Stehle","year":"2015","unstructured":"Stehle, P. & Kuhn, K. S. Glutamine: an obligatory parenteral nutrition substrate in critical care therapy. Biomed Res Int \n                           2015, 545467, doi:10.1155\/2015\/545467 (2015).","journal-title":"Biomed Res Int"},{"key":"5872_CR30","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1007\/BF01116556","volume":"5","author":"EA Newsholme","year":"1985","unstructured":"Newsholme, E. A., Crabtree, B. & Ardawi, M. S. The role of high rates of glycolysis and glutamine utilization in rapidly dividing cells. Biosci Rep \n                           5, 393\u2013400 (1985).","journal-title":"Biosci Rep"},{"key":"5872_CR31","doi-asserted-by":"publisher","first-page":"63S","DOI":"10.1177\/014860719001400406","volume":"14","author":"EA Newsholme","year":"1990","unstructured":"Newsholme, E. A. & Parry-Billings, M. Properties of glutamine release from muscle and its importance for the immune system. JPEN J Parenter Enteral Nutr \n                           14, 63S\u201367S (1990).","journal-title":"JPEN J Parenter Enteral Nutr"},{"key":"5872_CR32","doi-asserted-by":"crossref","unstructured":"Roth, E. Nonnutritive effects of glutamine. J Nutr \n                           138, 2025S\u20132031S, doi:138\/10S-I\/2025S [pii] (2008).","DOI":"10.1093\/jn\/138.10.2025S"},{"key":"5872_CR33","doi-asserted-by":"publisher","first-page":"e0165045","DOI":"10.1371\/journal.pone.0165045","volume":"11","author":"K Kratochwill","year":"2016","unstructured":"Kratochwill, K. et al. Addition of Alanyl-Glutamine to Dialysis Fluid Restores Peritoneal Cellular Stress Responses - A First-In-Man Trial. PLoS One \n                           11, e0165045, doi:10.1371\/journal.pone.0165045 (2016).","journal-title":"PLoS One"},{"key":"5872_CR34","doi-asserted-by":"crossref","unstructured":"Newsholme, P. Why is L-glutamine metabolism important to cells of the immune system in health, postinjury, surgery or infection? J Nutr \n                           131, 2515S-2522S; discussion 2523S-2514S (2001).","DOI":"10.1093\/jn\/131.9.2515S"},{"key":"5872_CR35","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1182\/blood.V86.4.1564.bloodjournal8641564","volume":"86","author":"A Spittler","year":"1995","unstructured":"Spittler, A. et al. Influence of glutamine on the phenotype and function of human monocytes. Blood \n                           86, 1564\u20131569 (1995).","journal-title":"Blood"},{"key":"5872_CR36","doi-asserted-by":"crossref","first-page":"2040S","DOI":"10.1093\/jn\/138.10.2040S","volume":"138","author":"J Wernerman","year":"2008","unstructured":"Wernerman, J. Clinical use of glutamine supplementation. J Nutr \n                           138, 2040S\u20132044S (2008).","journal-title":"J Nutr"},{"key":"5872_CR37","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1093\/ndt\/gfv440","volume":"31","author":"MR Lambie","year":"2016","unstructured":"Lambie, M. R. et al. Peritoneal inflammation precedes encapsulating peritoneal sclerosis: results from the GLOBAL Fluid Study. Nephrol Dial Transplant \n                           31, 480\u2013486, doi:10.1093\/ndt\/gfv440 (2016).","journal-title":"Nephrol Dial Transplant"},{"key":"5872_CR38","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1681\/ASN.2013030314","volume":"24","author":"M Lambie","year":"2013","unstructured":"Lambie, M. et al. Independent effects of systemic and peritoneal inflammation on peritoneal dialysis survival. Journal of the American Society of Nephrology: JASN \n                           24, 2071\u20132080, doi:10.1681\/ASN.2013030314 (2013).","journal-title":"Journal of the American Society of Nephrology: JASN"},{"key":"5872_CR39","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1002\/jcp.20339","volume":"204","author":"R Curi","year":"2005","unstructured":"Curi, R. et al. Molecular mechanisms of glutamine action. J Cell Physiol \n                           204, 392\u2013401, doi:10.1002\/jcp.20339 (2005).","journal-title":"J Cell Physiol"},{"key":"5872_CR40","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1038\/ni1552","volume":"9","author":"HC Hsu","year":"2008","unstructured":"Hsu, H. C. et al. Interleukin 17-producing T helper cells and interleukin 17 orchestrate autoreactive germinal center development in autoimmune BXD2 mice. Nat Immunol \n                           9, 166\u2013175, doi:10.1038\/ni1552 (2008).","journal-title":"Nat Immunol"},{"key":"5872_CR41","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.4049\/jimmunol.0903133","volume":"184","author":"S Xie","year":"2010","unstructured":"Xie, S. et al. IL-17 activates the canonical NF-kappaB signaling pathway in autoimmune B cells of BXD2 mice to upregulate the expression of regulators of G-protein signaling 16. J Immunol \n                           184, 2289\u20132296, doi:10.4049\/jimmunol.0903133 (2010).","journal-title":"J Immunol"},{"key":"5872_CR42","doi-asserted-by":"publisher","first-page":"1614","DOI":"10.4049\/jimmunol.1300479","volume":"191","author":"Y Ding","year":"2013","unstructured":"Ding, Y. et al. IL-17RA is essential for optimal localization of follicular Th cells in the germinal center light zone to promote autoantibody-producing B cells. J Immunol \n                           191, 1614\u20131624, doi:10.4049\/jimmunol.1300479 (2013).","journal-title":"J Immunol"},{"key":"5872_CR43","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.kint.2015.12.005","volume":"89","author":"E Ferrantelli","year":"2016","unstructured":"Ferrantelli, E. et al. The dipeptide alanyl-glutamine ameliorates peritoneal fibrosis and attenuates IL-17 dependent pathways during peritoneal dialysis. Kidney Int \n                           89, 625\u2013635, doi:10.1016\/j.kint.2015.12.005 (2016).","journal-title":"Kidney Int"},{"key":"5872_CR44","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1016\/j.ajpath.2010.12.034","volume":"178","author":"K Kratochwill","year":"2011","unstructured":"Kratochwill, K. et al. Interleukin-1 receptor-mediated inflammation impairs the heat shock response of human mesothelial cells. Am J Pathol \n                           178, 1544\u20131555, doi:10.1016\/j.ajpath.2010.12.034 (2011).","journal-title":"Am J Pathol"},{"key":"5872_CR45","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1158\/1541-7786.MCR-15-0147","volume":"13","author":"SA Patel","year":"2015","unstructured":"Patel, S. A. & Gooderham, N. J. IL6 Mediates Immune and Colorectal Cancer Cell Cross-talk via miR-21 and miR-29b. Mol Cancer Res \n                           13, 1502\u20131508, doi:10.1158\/1541-7786.MCR-15-0147 (2015).","journal-title":"Mol Cancer Res"},{"key":"5872_CR46","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2015\/929806","volume":"2015","author":"M Lopez-Anton","year":"2015","unstructured":"Lopez-Anton, M., Bowen, T. & Jenkins, R. H. microRNA Regulation of Peritoneal Cavity Homeostasis in Peritoneal Dialysis. BioMed Research International \n                           2015, 1\u20139, doi:10.1155\/2015\/929806 (2015).","journal-title":"BioMed Research International"},{"key":"5872_CR47","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1056\/NEJMoa1212722","volume":"368","author":"D Heyland","year":"2013","unstructured":"Heyland, D. et al. A randomized trial of glutamine and antioxidants in critically ill patients. N Engl J Med \n                           368, 1489\u20131497, doi:10.1056\/NEJMoa1212722 (2013).","journal-title":"N Engl J Med"},{"key":"5872_CR48","doi-asserted-by":"publisher","DOI":"10.2202\/1544-6115.1027","author":"GK Smyth","year":"2004","unstructured":"Smyth, G. K. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 3, Article3. doi:10.2202\/1544-6115.1027 (2004).","journal-title":"Stat Appl Genet Mol Biol 3, Article3"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-05872-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-05872-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-05872-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,23]],"date-time":"2022-12-23T02:14:43Z","timestamp":1671761683000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-05872-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,24]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["5872"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-05872-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,24]]},"assertion":[{"value":"16 February 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2017","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.A. is cofounder of Zytoprotec GmbH, a spin-off of the Medical University Vienna that holds the patent \u2018Carbohydrate-based peritoneal dialysis fluid comprising glutamine residue\u2019 (International Publication Number: WO 2008\/106702 A1). R.H., L.K. and K.K. are former employees of Zytoprotec GmbH. A.V. has received consulting and lecture fees from Baxter, Fresenius Medical Care and Amgen, travel funding\/congress fees from Baxter and Fresenius Medical Care and Research funding from Baxter (all unrelated to this trial). He has been a principal investigator in trials funded by Baxter, Fresenius and Zytoprotec. All other authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"6229"}}